

150 micrograms of tetracycline hydrochloride per milliliter (estimated). Further dilute an aliquot of the stock solution with sterile distilled water to the reference concentration of 0.24 microgram of tetracycline hydrochloride per milliliter (estimated).

(2) *Moisture*. Proceed as directed in § 436.201 of this chapter.

[43 FR 11174, Mar. 17, 1978 as amended at 44 FR 30333, May 25, 1979. Redesignated at 45 FR 16472, Mar. 14, 1980, and amended at 50 FR 19920, May 13, 1985]

Subpart G—Vaginal Dosage Forms

§ 446.667 Oxytetracycline hydrochloride-polymyxin B sulfate vaginal tablets.

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Oxytetracycline hydrochloride-polymyxin B sulfate vaginal tablets are tablets composed of oxytetracycline hydrochloride and polymyxin B sulfate with one or more suitable diluents, binders, lubricants, and preservatives. Each tablet contains oxytetracycline hydrochloride equivalent to 100 milligrams of oxytetracycline and polymyxin B sulfate equivalent to 100,000 units of polymyxin B. Its oxytetracycline content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of oxytetracycline that it is represented to contain. Its polymyxin B content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of units of polymyxin B that it is represented to contain. The loss on drying is not more than 3.0 percent. The oxytetracycline hydrochloride used conforms to the standards prescribed by § 446.67(a)(1). The polymyxin B sulfate used conforms to the standards prescribed by § 448.30(a)(1) of this chapter.

(2) *Labeling.* It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The oxytetracycline hydrochloride used in making the batch for

potency, loss on drying, pH, absorptivity, identity, and crystallinity.

(b) The polymyxin B sulfate used in making the batch for potency, loss on drying, pH, residue on ignition, and identity.

(c) The batch for oxytetracycline content, polymyxin B content, and loss on drying.

(ii) Samples required:

(a) The oxytetracycline hydrochloride used in making the batch: 10 packages, each containing approximately 300 milligrams.

(b) The polymyxin B sulfate used in making the batch: 10 packages, each containing approximately 300 milligrams.

(c) The batch: A minimum of 30 tablets.

(b) *Tests and methods of assay—(1) Potency—(i) Oxytetracycline content.* Proceed as directed in § 436.106 of this chapter, preparing the sample for assay as follows: Place a representative number of tablets into a high-speed glass blender jar containing sufficient 0.1N hydrochloric acid to obtain a stock solution of convenient concentration containing not less than 150 micrograms of oxytetracycline per milliliter (estimated). Blend for 3 to 5 minutes. Remove an aliquot of the stock solution and further dilute with sterile distilled water to the reference concentration of 0.24 microgram of oxytetracycline per milliliter (estimated).

(ii) *Polymyxin B content.* Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Grind a representative number of tablets into a fine powder and place this powder, accurately weighed, into a filter funnel with a solvent-resistant membrane filter of 1.0 micrometer porosity. Wash the powder with five 20-milliliter portions of acetone or until the yellow color has disappeared. Remove the filter and soak in 400 milliliters of 10 percent potassium phosphate buffer, pH 6.0 (solution 6), and blend. Quantitatively transfer to a 500-milliliter volumetric flask and adjust to volume with solution 6. Further dilute an aliquot with solution 6 to the reference concentration of 10 units of polymyxin B per milliliter (estimated).

(2) *Loss on drying.* Proceed as directed in § 436.200(b) of this chapter.

[43 FR 11174, Mar. 17, 1978, as amended at 50 FR 19920, May 13, 1985]

Subpart H—Rectal Dosage Forms [Reserved]

Subpart I [Reserved]

Subpart J—Certain Other Dosage Forms [Reserved]

PART 448—PEPTIDE ANTIBIOTIC DRUGS

Subpart A—Bulk Drugs

Sec.

- 448.10 Bacitracin.
- 448.10a Sterile bacitracin.
- 448.13 Bacitracin zinc.
- 448.13a Sterile bacitracin zinc.
- 448.15a Sterile capreomycin sulfate.
- 448.20a Sterile colistimethate sodium.
- 448.21 Colistin sulfate.
- 448.23 Cyclosporine.
- 448.25 Gramicidin.
- 448.30 Polymyxin B sulfate.
- 448.30a Sterile polymyxin B sulfate.
- 448.75 Tyrothricin.

Subpart B—Oral Dosage Forms

- 448.121 Colistin sulfate for oral suspension.
- 448.123 Cyclosporine oral dosage forms.
- 448.123a Cyclosporine oral solution.
- 448.123b Cyclosporine capsules.

Subpart C—Injectable Dosage Forms

- 448.210 Sterile bacitracin.
- 448.215 Sterile capreomycin sulfate.
- 448.220 Colistimethate sodium injectable dosage forms.
- 448.220a Sterile colistimethate sodium.
- 448.223 Cyclosporine for infusion.
- 448.230 Sterile polymyxin B sulfate.

Subpart D—Ophthalmic Dosage Forms

- 448.310 Bacitracin ophthalmic dosage forms.
- 448.310a [Reserved]
- 448.310b Bacitracin-neomycin sulfate-polymyxin B sulfate ophthalmic ointment.
- 448.310c Bacitracin ophthalmic ointment.
- 448.313 Bacitracin zinc ophthalmic dosage forms.
- 448.313a Bacitracin zinc-polymyxin B sulfate ophthalmic ointment.
- 448.313b Bacitracin zinc-neomycin sulfate-polymyxin B sulfate ophthalmic ointment; bacitracin zinc-neomycin sulfate-

polymyxin B sulfate hydrocortisone ophthalmic ointment.

- 448.321 Colistin sulfate for ophthalmic solution.
- 448.330 Polymyxin B sulfate-trimethoprim hemisulfate ophthalmic solution.

Subpart E—Otic Dosage Forms

- 448.421 Colistin sulfate-neomycin sulfate-thonzonium bromide-hydrocortisone acetate otic suspension.
- 448.430 Polymyxin B sulfate-hydrocortisone otic solution.

Subpart F—Dermatologic Dosage Forms

- 448.510 Bacitracin dermatologic dosage forms.
- 448.510a Bacitracin ointment.
- 448.510b—448.510c [Reserved]
- 448.510d Bacitracin-neomycin sulfate ointment.
- 448.510e Bacitracin-neomycin sulfate-polymyxin B sulfate ointment.
- 448.510f Bacitracin-polymyxin B sulfate topical aerosol.
- 448.513 Bacitracin zinc dermatologic dosage forms.
- 448.513a Bacitracin zinc-polymyxin B sulfate ointment.
- 448.513b Bacitracin zinc-neomycin sulfate ointment.
- 448.513c Bacitracin zinc-neomycin sulfate-polymyxin B sulfate ointment; bacitracin zinc-neomycin sulfate-polymyxin B sulfate hydrocortisone ointment.
- 448.513d Bacitracin zinc-polymyxin B sulfate topical powder.
- 448.513e Bacitracin zinc-polymyxin B sulfate topical aerosol.
- 448.513f Bacitracin zinc ointment.

Subpart G—Vaginal Dosage Forms [Reserved]

Subparts H–I [Reserved]

Subpart J—Certain Other Dosage Forms

- 448.910 Bacitracin for prescription compounding.
- 448.913 Bacitracin zinc for prescription compounding.
- 448.930 Polymyxin B sulfate in certain other dosage forms.
- 448.930a Polymyxin B sulfate for prescription compounding.
- 448.930b Sterile polymyxin B sulfate-benzalkonium chloride urethral lubricant.

AUTHORITY: 21 U.S.C. 357.

SOURCE: 39 FR 19115, May 30, 1974, unless otherwise noted.